Osteocalcin: from marker of bone formation to hormone; and bone, an endocrine organ

DOI: http://dx.doi.org/10.4321/S1889-836X2020000400007

Rubert M1, De la Piedra C2
1 Hospital Support Team. Palliative care. University Hospital of Móstoles. Móstoles. Madrid (Spain)
Madrid (Spain)

Summary
Osteocalcin is a protein synthesized by the osteoblast. Before being released into the extracellular matrix, human osteocalcin undergoes gamma-carboxylation, as gamma-carboxy-glutamic acid binds at positions 17, 21 and 24. Part of the carboxylated and decarboxylated osteocalcin passes into the circulation. Since its discovery in the late 70s, it has been used as a marker of bone formation as it is an osteoblastic product and its role in the body is unknown. In recent years, osteocalcin has been identified as a hormone. Bone is considered an endocrine organ. Osteocalcin acting as a hormone is the decarboxylated form. Osteocalcin is involved in glucose homeostasis, skeletal muscle function, brain development, male fertility, hepatic steatosis, and arterial calcification. All of these facts have actually been tested in mice, but there is strong evidence that this could occur in humans. We are faced with facts that, if proven, would have enormous clinical significance.

Key words: osteocalcin, hormone, glucose, insulin, skeletal muscle, brain development, hepatic steatosis, arterial calcification.

Osteocalcin is a protein synthesized by the osteoblast. It was identified in the late 1970s and in humans contains 49 amino acids1. Before being released into the extracellular matrix, osteocalcin undergoes gamma-carboxylation, as gamma-carboxy-glutamic acid binds at positions 17, 21 and 24. A gamma-carboxylase is involved in this reaction and the presence of vitamin K is required (Figure 1). The presence of the two carboxyl groups causes gamma-carboxylated osteocalcin to have a high affinity for calcium and, when released into the extracellular environment, binds in a large proportion to hydroxyapatite in bone. A part of this gamma-carboxylated osteocalcin and also non-carboxylated osteocalcin remain in the circulation2. Only 10-30% of the synthesized osteocalcin reaches the circulation, and the rest remains attached to the bone matrix. Non-carboxylated osteocalcin represents 1/3 of total osteocalcin. During resorption, when the bone matrix is destroyed, part of the osteocalcin that is bound to the bone passes into the circulation2. Osteocalcin is only synthesized by osteoblasts and is the most abundant non-collagenous protein in the extracellular matrix and is the tenth most abundant protein in vertebrates3. Since first reported, its levels were correlated with bone formation4. For all researchers working in bone metabolism, having a new bone formation marker was a breakthrough when the only markers of remodeling that were available up to that time were hydroxyproline and total alkaline phosphatase. The bone isoenzyme of alkaline phosphatase could also be measured by a rather complex method by electrophoresis. Osteocalcin has been used for many years as a marker of bone formation in practically all the work carried out in this regard. It is used less since 2011 when the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommended that the N-terminal propeptide of type I collagen (PINP) be used as a maker of formation and the C-terminal β-telopeptide of type I collagen or β-crosslaps (β-CTX) as a marker of resorption in clinical studies on osteoporosis5.
For many years, and despite its abundance, the role of osteocalcin in the body was unknown. Due to its post-translational modification, it was thought to be involved in bone mineralization. But when mice without osteocalcin (osteocalcin-/-) were obtained, it was found that these mutants presented totally normal mineralization, making it clear that the function of osteocalcin was not related to bone mineralization.

Bone contains osteoclasts, cells whose function is to destroy bone, and this active destruction of mineralized bone requires energy. Bone formation also requires energy. Thus, researcher groups such as Karsenty et al. hypothesized that bone modeling and remodeling must be associated with the regulation of energy metabolism. Probably, the amount of energy from the active destruction of the bone is proportional to the surface occupied by it. This energy requirement is probably very high, since bone resorption does not occur as an isolated event, but in the context that there must be a coordinated regulation of a biphasic function called modeling during childhood and remodeling in adult life. This is why the aforementioned authors hypothesized that bone modeling and remodeling must be linked to the regulation of energy metabolism. This vision of a coordinated regulation of bone mass and energy metabolism is supported by clinical evidence. For example, longitudinal bone growth stops in children and bone mass declines in adults with severely limited access to food (ie, energy). Furthermore, another link between bone remodeling and energy metabolism is that bone mass always declines in both sexes when gonadal function decreases. Considering these observations, it is concluded that there must be a coordinated regulation of bone growth/mass, energy metabolism and reproduction.

We previously mentioned that mice (osteocalcin-/-) had normally mineralized bones, but they develop some phenotypes that can only be explained, given the site of synthesis of osteocalcin and its abundance, if this molecule were acting as a hormone. Indeed, the mutant mice (osteocalcin-/-) had more visceral fat than the controls and also had fewer offspring. The systematic study of these phenotypes established that bone must be an endocrine organ and that the hormone it secretes, osteocalcin, affects energy metabolism and fertility. In other words, there is a coordinated regulation, endocrine in nature of energy metabolism and reproduction. A fundamental part is that the bone would be an endocrine organ and not the receptor of the action of hormones.

At this time, the knowledge of the mechanisms of action of osteocalcin in its target organs is a work in progress. For example, increased adiposity in mice (osteocalcin-/-) could be associated with a decrease in energy expenditure and not an increase in appetite (another function regulated by bone). The molecular basis of this phenomenon has not yet been discovered.

OSTEOCALCIN AND GLUCOSE HOMEOSTASIS

In a study by Wei et al., in which they cultured mouse osteoblasts with pancreatic islets, increased insulin expression in the islets was observed. Osteoblasts did not increase the expression of any other hormones secreted by the pancreatic islets. When osteoblasts from mice (osteocalcin-/-) were added, this insulin expression did not occur. Thus, it was shown that osteoblasts are endocrine cells that regulate insulin expression and that osteocalcin is the hormone responsible for this action. Mice (osteocalcin-/-) on a normal diet were also found to be hyperglycemic and hypoinsulinemic. Insulin secretion was decreased in the absence of osteocalcin.

In this same study, a glucose tolerance test showed that the mice (osteocalcin-/-) were glucose intolerant because they had a decrease in insulin expression. Wei et al. stated that the fact that osteocalcin regulates glucose metabolism is not synonymous with bone being the origin of diabetes. It simply increases the regulatory landscape of glucose metabolism.

Research carried out in rats with normal diet shows that osteocalcin is necessary and sufficient to promote the proliferation of β cells in the pancreatic islets, to promote the expression and secretion of insulin and to promote glucose uptake in peripheral tissues, and hence glucose homeostasis.
The receptor that mediates the osteocalcin signal in β-
pancreatic cells and other peripheral tissues is a G-protein
coupled receptor called GPR6a13. Specific gene deletion
and other genetic experiments have established that, in
vivo, osteocalcin is, without a doubt, the ligand that ex-
plains the regulation of glucose homeostasis through
GP6α10. The biological importance of the regulation of os-
teocalcin in glucose homeostasis has been verified in nor-
mal mice fed a high fat diet. Exogenous osteocalcin almost
completely rescues glucose intolerance in these animals14.
It was very important to know if these actions were
produced by carboxylated or decarboxylated osteocalcin.
In bacteria there is no gamma-carboxylation and thus re-
combinant bacterial osteocalcin that was not gamma-car-
boxylated could be produced. This non-carboxylated
osteocalcin was able to induce insulin expression in the
pancreatic islets, indicating that the non-carboxylated
form of osteocalcin is the one that acts as a hormone6.
Osteoblasts have insulin receptors on their surface, and
it is of great interest that insulin and osteocalcin are
involved in a regulatory loop. So the insulin signal in the
osteoblasts is required for good glucose homeostasis
throughout the body9.
Mice that do not have insulin receptors on osteoblasts,
when eating a normal diet, experience a decrease in the ac-
tive circulating form of osteocalcin, a decrease in insulin se-
cretion, glucose intolerance and insulin resistance. The
insulin signal on osteoblasts inhibits the expression of os-
teoprotegerin and favors bone resorption. The low pH that
occurs under osteoclasts favors the formation of decar-
boxylated osteocalcin, which is the active form of osteocal-
cin. This active osteocalcin acts again on the β-pancreatic
cells and new insulin is formed that acts again on the osteo-
blast and the cycle begins again (Figure 2)15.

Osteocalcin and Skeletal Muscle
A simple injection of exogenous osteocalcin immediately
before exercise or chronic administration of this hormone
for 1 month, not only increases the exercise capacity of
young mice but also restores the exercise capacity of older
mice18. At the same time as increasing muscle strength in
aged mice, chronic administration of osteocalcin promotes
muscle growth18. That is, exogenous osteocalcin is not only
necessary but sufficient to reverse the decline in exer-
cise capacity and muscle mass observed in older mice18.
Osteocalcin signal on skeletal muscle is carried out
through the GPR6α receptor14. Osteocalcin has been
shown to regulate nutrient uptake and catabolism in mus-
cle during exercise. Glucose, the main nutrient used by
skeletal muscle to generate energy during exercise, is sto-
red in myofibers as glycogen. The degradation of glycogen
in skeletal muscle during exercise is lower in mice that do
not have the GPR6α receptor and in mice (osteocalcin−/−),
showing that osteocalcin favors glycogenolysis.
It has also been observed that the accumulation of tri-
carboxylic cycle intermediates in skeletal muscle seen in
mice after exercise is not observed in mice (GPR6α−/−), il-
dicating that there is no ATP input from the tricarboxylic
cycle. Over an extended period of exercise, when animals
deplete their glycogen stores, the uptake and catabolism of
fatty acids increases in skeletal muscle14. Osteocalcin favors
the oxidation of fatty acids in myofibers. The osteocalcin
signal in the myofibers promotes the uptake and catabo-
lism of glucose and fatty acids during exercise, which is why
a decrease in physical activity is observed in mice (os-
teocalcin−/−) and (GPR6α−/−) when compared to controls20.

For decades it has been common knowledge that exercise induces changes in the immune system21. Inter-
leukin 6 (IL6) was the first molecule that was seen to be
released into the blood in response to muscle contrac-
tion22. IL6 promotes glucose uptake and fatty acid oxida-
tion in skeletal muscle, increasing glucose production in
the liver and lipolysis in adipose tissue23.
Exercise induces bone resorption and the production of
bioactive osteocalcin. Mice (IL6−/−) after exercise do not
increase bone resorption markers or bioactive osteo-
calcin, as happens in healthy mice. This suggests the exis-
tence of a loop between bone (via osteocalcin) and muscle
(via IL6) that promotes adaptation to exercise20. Thus:
- Osteocalcin increases the uptake of nutrients and their catabolism in skeletal muscle.
- Osteocalcin increases the secretion of IL6 in skeletal muscle. This leads to the generation of extra-muscular
  glucose and fatty acids24.
- IL6 increases the production of bioactive osteocalcin20.

Osteocalcin and Brain Development
Osteocalcin is necessary for the development of the brain
and for its function. Its absence in mice produces a pro-
found deficit in spatial knowledge and memory and an
exacerbation of anxiety. Osteocalcin could prevent low-
ering of consciousness due to age25.
The brain-derived neurotrophic factor BDNF, a well-
known molecule that participates in memory, dependent
on the hippocampus, is the mediator of the regulation of
osteocalcin on cognitive function26. Non-carboxylated
osteocalcin is able to stimulate the dynamics of BDNF
vesicle transport towards synaptic in rat neurons25.

Khrimian et al.27 identified the receptor that transfers
the signal from osteocalcin to neurons. It is Gpr158, a G
protein-bound receptor expressed on neurons in the
CA3 region of the hippocampus, which transmits the os-
teocalcin signal through inositol 1,4,5-triphosphate and
a brain-derived neurotrophic factor. This is very impor-
tant for future therapeutic actions.

Osteocalcin and Male Fertility
Decarboxylated osteocalcin acts on the Leydig cells of the
testes, promoting the biosynthesis of testosterone20.
Decarboxylated osteocalcin acts through the GPR6α re-
ceptor, as it did on β-pancreatic cells.
Osteocalcin has also been shown to act via a pan-
creas-bone-testes axis that regulates, independently and
in parallel to the hypothalamic-pituitary-testes axis,
male reproductive function, promoting testosterone
biosynthesis20.
OSTEOCALCIN AND HEPATIC STEATOSIS
In mice on a high-fat diet, daily injections of osteocalcin of 3 or 30 ng/g of body weight/day partially restore insulin sensitivity and glucose tolerance. Furthermore, mice treated with intermittent injections of osteocalcin exhibited increased energy expenditure and were protected from diet-induced obesity. Finally, the fatty diet-induced hepatic steatosis was completely avoided in the mice that received osteocalcin daily. These results show that daily osteocalcin injections improve glucose management and prevent the development of type 2 diabetes.

OSTEOCALCIN AND ARTERIAL CALCIFICATION
In the “bone-vascular calcification paradox” there is high calcification in the vessels, leading to arterial stiffness and cardio-vascular disease, and reduced calcification in the bone leading to osteoporosis and bone fracture. This leads to the hypothesis that bone metabolism and cardiovascular disorders could have common pathogenic pathways, leading to the expression “bone-vascular axis.” Several molecules seem to play a role in this axis, and one of them would be osteocalcin.

Rashdan et al. maintain the hypothesis that osteocalcin regulates the calcification of vascular smooth muscle cells. Immunohistochemistry reveals the co-localization of osteocalcin with calcification of vascular smooth muscle cells in calcified plaques of carotid arteries. Osteocalcin involvement in the development of atherosclerosis is supported by a recent meta-analysis by Millar et al., in which a relationship between osteocalcin and atherosclerosis markers is observed in histological samples. In this same study, the authors found no differences between osteocalcin levels in patients with and without vascular events. That is, osteocalcin seems to be a marker only of the calcification process.

OSTEOCALCIN IN HUMANS
So far, all the review carried out on the role of osteocalcin as a hormone has focused on experiments in mice or rats. It is extremely important to know if these facts can be transferred to humans, with the clinical implications that this would entail.

A systematic review of the literature conducted between 2007 and 2014 identified 82 studies that observed that serum levels of decarboxylated or total osteocalcin are negatively correlated with blood glucose, insulin resistance, obesity, or markers of metabolic syndrome. Furthermore, some of the human data support a role for osteocalcin in insulin secretion.

Treatment with bisphosphonates has been found to decrease non-carboxylated osteocalcin in serum and that levels of it and/or markers of insulin sensitivity or secretion are positively correlated with markers of bone resorption in humans.

It has also been seen that patients with a dominant form of osteopetrosis due to a defect in osteoclast activity are characterized by decreased levels of decarboxylated osteocalcin and hypoinsulinemia.

Changes in osteocalcin levels, following bisphosphonate treatments, are associated with changes in body mass and fat.

Oury et al. analyzed a cohort of patients with testicular failure and identified 2 individuals with a variant in one of the GPRC6a domains. These patients had glucose intolerance and insulin resistance.

Osteocalcin levels have been compared between patients with type 2 diabetes mellitus and the non-diabetic population, with diabetics having lower levels of osteocalcin. Patients with metabolic syndrome also have lower levels of total osteocalcin than healthy individuals.
In addition, there is a correlation between total and de-carboxylated osteocalcin with markers of glycemic status and other cardio-metabolic parameters. These authors point out the need to delve into these findings and their possible participation in human health, as well as analyze their possible therapeutic potential.

An observational study assessed the association between serum levels of osteocalcin and knowledge capacity in healthy adults, showing that it is positively correlated with measures of global knowledge in elderly women. In children and adolescents with nonalcoholic fatty liver, the concentration of osteocalcin is inversely correlated with liver enzymes and with the severity of the disease.

Smith et al., in a study carried out in 2020, considered the normal values of decarboxylated and carboxylated osteocalcin in adult men. These values should be included in future studies in clinical trials and associated with the prediction of events such as fractures or risk of diabetes. The amount of evidence on the multi-organ effects of decarboxylated osteocalcin, supported by the facts demonstrated in vivo and in vitro, indicates the need to deepen these findings and its possible participation in human health, as well as to analyze its possible therapeutic potential.

**CONCLUSIONS**

The discoveries made in recent years concerning the role of osteocalcin as a hormone and bone as an endocrine organ are truly surprising. Osteocalcin, which for bone metabolism researchers was simply a marker of bone formation with no known function.

In mice, osteocalcin is involved in glucose homeostasis, skeletal muscle function, brain development, hepatic steatosis, male fertility, and arterial calcification.

We begin to find works that seem to anticipate that this could also happen in humans.

It is extremely important to address this type of research in humans, because if what happened in humans were similar to what happens with osteocalcin in mice, the therapeutic implications of this compound would be extremely interesting.

**Conflict of interests:** The authors declare no conflict of interest.
Bibliography


